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Trace-amine associated receptor 1 and vulnerability
to methamphetamine use disorders
Methamphetamine (MA) is a powerful and highly addictive psychostimulant which can greatly
damage the health of the user. As data from the National Survey on Drug Use and Health indicates that
14.7 million people have used MA at least once in their lifetime, it is evident that this drug poses a threat
that is detrimental to our society (NIDA, 2017). MA acts on various reuptake proteins to block the
reuptake of catecholamines, including dopamine, norepinephrine, and serotonin, in neurons, which
increases the amount of these in the brain. (Cruickshank & Dryer, 2009). This action leads to the
rewarding effects of the drug, such as euphoria and wakefulness, but can also induce aversive effects such
as stress and anxiety. The balance between the sensitivity to the rewarding and aversive effects will
determine drug intake, whereby one who experiences heightened sensitivity to the aversive effects will
consume less MA (Phillips, et al., 2015). Long term MA use can lead to brain deteriorations including
rapid cognitive decline, psychotic disorders, hallucinations, and depression (Prakash et al., 2017). The
resulting neurological changes caused by prolonged MA intake contribute to the chronic nature of
addiction as well as high prospect of relapse (Phillips, et al., 2015). Currently, there are no approved
treatments for MA addiction despite the harm it causes in the lives of so many (NIDA 2017).
Risk of chronic MA addiction is attributed to both genetic and environmental factors but the
specific genes that contribute to MA use have not yet been thoroughly explored (Phillips, et al., 2015).
Researchers at the Oregon Health and Science University have utilized a bidirectional selective breeding
process to create mice of both high (MAHDR) and low (MALDR) voluntary MA consumption (Phillips,
et al., 2015). Quantitative trait locus (QTL) mapping found a region on chromosome 10 that accounts for
about 50% of the difference in MA intake between the lines (Harkness et al., 2015). Research suggests
that the trace-amine associated receptor (Taar1) gene, which lies within this region, plays a large role in
the intake difference (Reed et al., 2017). MAHDR mice have a nonfunctional version of this gene
whereas MALDR mice have at least one functional copy (Harkness et al., 2015). Both MA and Taar1
agonist, RO-5263397, have been shown to induce aversive effects and hypothermia in MALDR mice but
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not in MAHDR mice since they have a non-functional receptor (Harkness et al., 2015). To test the effects
of the Taar1 receptor specifically, the Phillips lab has used the CRISPR-Cas9 method to knock in the
functional version of Taar1 into MAHDR mice, who would otherwise have the nonfunctional version.
MAHDR mice with the knock-in Taar1+/+ showed a decreased MA intake in behavioral tests, closer to the
intake of MALDR mice (Harkness et A., 2015). However, sensitivity to the rewarding and aversive
effects of MA has not yet been tested.
Our study sought to investigate the role of the Taar1 receptor in the aversive effects of MA. Two
different lines of MAHDR mice were used, one with a nonfunctional receptor, Taar1m1J/m1J, and the other
with the functional version, Taar1+/+, that has been knocked in via the CRISPR-Cas9 method. Both were
tested with the Taar1 agonist, RO5263397, in a conditioned place preference (CPP) procedure which is
used to evaluate a drug's rewarding and aversive effects (Shabani et al., 2011). Our prediction was that the
Taar1 agonist would induce aversive effects in the Taar1+/+ mice, and thus show conditioned place
aversion (CPA), and that it would not induce aversive effects in Taar1m1J/m1J mice and thus show no
conditioned place preference or aversion. Locomotor activity and body temperature in response to the
drug were also tested.
The overarching goal of this study is to identify druggable gene targets for treating chronic MA
addiction. Increasing our understanding of the Taar1 receptor will contribute to our overall understanding
of MA intake. Taar1 has already been identified as a target for therapeutic drugs to treat MA addiction so
understanding the mechanisms of this receptor in its relation to the how it effects MA intake will bring us
closer to that goal.

Methods
Animals
The care and use of our mice in this experiment was approved by Grand Valley State University’s
Institutional Animal Care and Use Committee. Two identical cohorts of mice were tested, each group
containing 48 mice, with equal numbers of males and females. Mice were housed in acrylic plastic
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shoebox cages (28.5 x 17.5 x 12 cm) with Bed-O-CobTM bedding at 2-3 mice per cage, consisting mostly
of mice from the same sex and line- the exception being several female cages where lines were mixed to
accommodate for testing order. All mice had free access to rodent chow (LabDiet Rodent 5001) and
water. Temperature in the colony room was maintained at 21 +/- 1 degrees Celsius and lighting was kept
on a 12:12-h light:dark cycle with lights on at 0600 h. The MADR mice were acquired from the selective
breeding process at Oregon Health & Science University.

Drug Preparation
The drug used in our experiment was the Taar1 agonist, RO-525639. The drug was dissolved in
3% Tween to the appropriate dose. Tween was diluted in pure water and was also used as a vehicle
solution. Drug and vehicle were administered intraperitoneally (IP).

Apparatus
For CPP testing we used a two-compartment place preference apparatus (Med Associates, St
Albans, VT, USA). These boxes consisted of two separate chambers (16.76 x 12.7 x 12.7 cm) with
different material clues. One side had white walls with stainless steel mesh flooring while the other had
black walls with stainless steel grid flooring. A door existed between these two chambers which remained
closed during conditioning and open during preference testing. Both chambers were topped with plastic
hinge lids containing a light source and also contained infrared photobeam detectors in the lower walls to
detect locomotor activity. The apparatuses were held in sound-dampening cabinets, closed during testing
to eliminate outside noise. Med Associates software (Med Associates, St Albans, VT, USA) and
equipment was used for CPP data collection.

Conditioned Place Preference (CPP)
We used an unbiased CPP procedure where the drug was administered immediately before each
animal was placed in a chamber. An initial, drug free, preference test was taken to identify
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preconditioning bias and give a base to contrast against once post conditioning tests were completed.
However, drug group and conditioning floor was assigned to each animal independent of the initial test.
On each experiment day mice were moved from the colony room to the experiment room and allowed to
acclimate for one hour before testing. During experimentation, mice were weighed, injected, and then
placed immediately into the CPP box. The experiment consisted of the initial preference test, 12
conditioning days, a day of drug free preference testing, and a day of drug present preference testing. The
initial pre-CPP test was conducted the day before conditioning began. Mice were injected with vehicle
solution and given access to both chambers of the CPP box for 30 min.
During conditioning days mice were injected with either Taar1 agonist or vehicle solution and
then were paired with the appropriate floor and the door between floors was closed. For each animal, drug
and vehicle were administered on alternating days for 12 days, each being paired to a specific floor on six
of those days. An animal receiving drug on the grid and vehicle on the mesh was considered grid positive
(G+) whereas an animal receiving drug on the mesh and vehicle on the grid was considered grid negative
(G-). We counterbalanced the G+ and G- groups across all animals considering sex, genotype, and
dosage.
After conditioning sessions, CPP tests were conducted both with and without drug present. Drugfree CPP test was the same test as the pre-CPP test and was conducted 2 days after conditioning sessions.
Then, 2 days later, the drug-present CPP test was conducted. In the drug-present test, all mice were given
the same drug dose that they received during the conditioning days. In both CPP tests the initial floor
placement was the same for each mouse as the pretest.

Temperature measurements
Temperature measurements were taken three days after the CPP study in a 2-day period. Baseline
rectal temperature was taken and mice were subsequently injected with drug or vehicle. Temperature was
then taken again at 60 min, 120 min, and 180 min after injection. We used the even and odd conditioning
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days as a template to determine whether each mouse would receive drug or vehicle on the first
temperature day. Each mouse was given the same drug dosage it received during conditioning.

Results
Conditioned Place Preference
Our study observed compelling CPA in Taar1+/+ mice in response to the Taar1 agonist (Figure 1
and 2). These mice spent significantly more time on the floor paired with vehicle when tested at the end
of conditioning. Both drug doses induced this aversion and the differences between the two doses was
minimal. The aversion response was seen in both drug free and drug present test days but was amplified
in the drug present. As expected, neither aversion nor preference was observed in the Taar1m1J/m1J mice.
Locomotor Activity during CPP test
The Taar1 agonist suppressed locomotor activity in the Taar1+/+ mice but did not suppress the
locomotor activity in Taar1m1J/m1J mice (Figure 3). This is similar to the effect that MA has on high and
low drinking MA lines whereby MA suppressed locomotor activity in low MA drinking mice but not high
MA drinking mice (Shabani et al., 2011). It was also observed that the Taar1+/+ mice have a lower innate
locomotor activity than the Taar1m1J/m1J mice, even before exposure to the Taar1 agonist.
Thermic Response
In response to the drug, Taar1+/+ mice experienced significant acute hypothermia, whereas,
Taar1m1J/m1J mice did not show a change in temperature (Figure 4). Drug dose had very little impact on
the hypothermic response in Taar1+/+ mice. Hypothermic response was strongest at the 60 minutes time
point.
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Discussion
Our study examined the function of the Taar1 receptor in MA use disorders by pharmacologically
and genetically manipulating the Taar1 receptor. The knock-in of the functional Taar1 seems to bring
back the sensitivity to the aversive effects of MA and in our case sensitivity to the aversive effects of the
Taar1 agonist. The Taar1 agonist induced strong aversive effects in Taar1+/+ knock-in mice, the mice
with the functional receptor, whereas it failed to have any appreciable effect in the Taar1m1J/m1J mice, that
have a non-functional Taar1 receptor. The Taar1 agonist suppressed locomotor activity during
conditioning days and CPP test days in Taar1+/+ mice, but not in the Taar1m1J/m1J mice. Interestingly,
Taar1+/+ mice also had a lower innate locomotor activity than Taar1m1J/m1J mice. The Taar1 agonist
induced hypothermia in Taar1+/+ mice, but had no effect on temperature in Taar1m1J/m1J mice. Our study
shows strong evidence that insensitivity to MA’s aversive effects in high MA drinking mice (Taar1m1J/m1J)
is specifically controlled by the Taar1 receptor. Therefore, exploring this receptor for development of
drugs that curb MA intake is warranted.
The CPP tests showed that only the Taar1+/+ mice were sensitive to the aversive effects of the
Taar1 agonist. Taar1 agonist doses chosen in this study seemed equally effective in inducing conditioned
place aversion in the knock-in mice. Our study is similar to the MA-induced CPA studies with high and
low MA drinkers. Molecularly, MA is considered a weak agonist to the Taar1 receptor. These studies
have shown that MA is effective in inducing CPA only in the MA low drinkers which have the functional
version of Taar1 receptor. Other work done in Dr. Shabani’s lab has indicated that MA low drinking mice
are highly sensitive to the aversive effects of Taar1 agonist. Our study, in which high MA drinking mice
have had the MA-induced CPA trait rescued by the genetic manipulation of having the functional version
of Taar1 inserted in their genome, gives strong evidence to the hypothesis that the aversive effects of MA
are mainly mediated via Taar1 receptor.
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Taar1 receptor seems to influence locomotor activity significantly. Previous CPP studies with
high and low MA drinking mice have shown that MA induced significantly higher locomotor activity in
MAHDR mice than MALDR mice. MA is a psychostimulant that, among many other effects, also
increases locomotor activity in general. The lower locomotor activity in the low MA drinking mice in
response to MA could be explained by the MA-induced activation of Taar1 receptor. This hypothesis is
supported in our study in which Taar1 agonist suppressed locomotor activity in Taar1+/+ mice, but not in
high MA drinking mice. Interestingly, innate locomotor activity was lower for the Taar1+/+ mice than
Taar1m1J/m1J mice. How Taar1 receptor influences locomotor activity is not known, and is something our
lab is interested to find out.
Thermic response measurements also revealed a significant difference in response to the Taar1
agonist between the two mice lines. Taar1+/+ mice showed acute hypothermia when injected with Taar1
agonist with the largest drop in body temperature occurring 60 minutes after injection. Taar1m1J/m1J mice
did not experience a change in body temperature when injected with the agonist. Dose effects were
minimal, and very much as expected based on previous studies with low MA drinking mice in Dr.
Shabani’s lab. Thermic response to Taar1 agonist in this study is similar to what Dr. Shabani’s lab found
with identical studies in low MA drinking mice. It is not known whether these thermic responses
influence any of the sensitivity to the aversive effects of Taar1 agonist. Future experiments will explore
this important question.
Conclusion
Our study found that in conditioned place preference tests Taar1 agonist, RO-525639, induced
conditioned place aversion in Taar1+/+ mice and failed to induce either preference or aversion in
Taar1m1J/m1J mice. Furthermore, the Taar1 agonist also suppressed locomotor activity and caused acute
hypothermia in Taar1+/+ mice and failed to cause either in Taar1m1J/m1J mice. These results support the
hypothesis that the Taar1 plays an important role in the sensitivity to the aversive effects of MA and thus
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MA intake. The Taar1 gene is an important druggable target to pursue in the fight against MA use
disorders. Laboratories around the world are looking closely into the TAAR1 function in drug use
disorders and our results will make an important contribution in understanding TAAR1 gene role in drug
use disorders.
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Appendix

Figure 1. (A-B) MAHDR-Taar1 m1J/m1J mice failed to exhibit RO-5256390-induced conditioned place aversion in
both drug-free and drug-present preference tests. (C-D) MAHDR-Taar1 +/+ mice exhibit RO-5256390-induced
conditioned place aversion in both drug-free and drug-present preference tests. (A-D) Shown are mean ± SEM
sec/min on the grid floor during the 30-min drug-free and -present CPP tests in mice conditioned with RO-5256390
on the grid/black (G+) or on the mesh/white (G-) side of the box. n = 10-13 per sex per dose. ***p<.001 for the
means comparison of G+ and G- groups.
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Figure 2. In a Pre-Test CPP procedure naive MAHDR-Taar1 m1J/m1J and MAHDR-Taar1 +/+ mice belonging to the
G+ or G- group did not show any difference in preference.
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Figure 3. MAHDR-Taar1 m1J/m1J mice showed a higher innate locomotor activity than MAHDR-Taar1 +/+
mice. MAHDR-Taar1 m1J/m1J mice exhibited a small but significant increase in locomotor activity on the
drug free test day compared to the pretest and drug present test days. MAHDR-Taar1 +/+ mice showed a
significant decrease in locomotor activity in response to the Taar1 agonist, RO-5256390, on the drug
present test day. ***p<.0001, *p<.05 mean difference between pre-test CPP and either drug-free or drugpresent.
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Figure 4. MAHDR-Taar1 m1J/m1J mice show no significant change in temperature in response the Taar1 agonist,
RO-5256390, compared to vehicle. MAHDR-Taar1 +/+ mice exhibit strong hypothermia in response to both doses
of Taar1 agonist. The strongest hypothermic response occurred 60 minutes after injection. *p<.05 mean difference
between vehicle and corresponding drug dose.

